Skip to main content
    O

    Omnicell Inc (OMCL)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $35.44
    +0.41 (+1.17%)

    Market Cap: $1.61B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Omnicell Inc (OMCL) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Omnicell (OMCL) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Omnicell reported EPS of $0.36, above the $0.24 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    85%(34/40)
    Avg Surprise
    +58.09%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.39
    Range$0.14 - $0.45
    10 analysts
    Revenue Consensus
    $304.53M
    Range$290.52M - $315.95M
    10 analysts
    Reports Apr 26, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.45
    Range$0.33 - $0.62
    7 analysts
    EPS Revisions
    4
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$0.44+2.3%
    60d ago$0.44+2.3%
    30d ago$0.44+2.3%
    7d ago$0.44+2.3%
    Current$0.45
    Revenue Consensus
    $304.51M
    Range$298.92M - $312.02M
    7 analysts

    Next Report

    OMCL has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 2.5% below the $0.40 reported for the quarter ended Dec 31, 2025.

    OMCL Earnings Call

    The latest OMCL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, OMCL beat 34, missed 4 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $307.85M, down 0.9% from $310.63M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.36$0.24N/A+50.00%Beat-29.4%81 up, 5 downOct 29, 2026$307.85M
    Jun 30, 2026$0.70$0.31N/A+125.81%Beat+55.6%87 up, 0 downJul 30, 2026$312.21M
    Mar 31, 2026$0.55$0.33$0.29 - $0.41+66.67%Beat+111.5%81 up, 0 downApr 28, 2026$309.88M
    Dec 31, 2025$0.40$0.50$0.46 - $0.61-20.00%Miss-33.3%81 up, 0 downFeb 5, 2026$313.98M
    Sep 30, 2025$0.51$0.36$0.32 - $0.42+41.67%Beat-8.9%83 up, 3 downOct 30, 2025$310.63M
    Jun 30, 2025$0.45$0.27$0.22 - $0.32+66.67%Beat-11.8%71 up, 0 downJul 31, 2025$290.56M
    Mar 31, 2025$0.26$0.20$0.16 - $0.25+30.00%Beat+766.7%80 up, 0 downMay 6, 2025$269.67M
    Dec 31, 2024$0.60$0.58$0.55 - $0.61+3.45%Beat+81.8%99 up, 0 downFeb 6, 2025$306.88M
    Sep 30, 2024$0.56$0.42$0.34 - $0.47+33.33%Beat-9.7%80 up, 0 downOct 30, 2024$282.42M
    Jun 30, 2024$0.51$0.14$0.10 - $0.18+264.29%Beat-10.5%91 up, 0 downAug 1, 2024$276.79M
    Mar 31, 2024$0.03-$0.09-$0.21 - -$0.04+133.33%Beat-92.3%90 up, 0 downMay 2, 2024$246.15M
    Dec 31, 2023$0.33$0.15$0.09 - $0.22+120.00%Beat0.0%90 up, 0 downFeb 8, 2024$258.85M
    Sep 30, 2023$0.62$0.48$0.42 - $0.49+29.17%Beat-38.0%71 up, 0 downNov 2, 2023$298.66M
    Jun 30, 2023$0.57$0.28$0.24 - $0.34+103.57%Beat-32.1%90 up, 0 downAug 1, 2023$298.97M
    Mar 31, 2023$0.39$0.07$0.02 - $0.11+457.14%Beat-53.0%90 up, 0 downMay 2, 2023$290.63M
    Dec 31, 2022$0.33$0.09$0.03 - $0.21+266.67%Beat-64.1%80 up, 1 downFeb 28, 2023$297.67M
    Sep 30, 2022$1.00$0.95$0.83 - $0.99+5.26%Beat-7.4%90 up, 0 downNov 2, 2022$348.06M
    Jun 30, 2022$0.84$0.85N/A-1.18%Miss-13.4%N/A0 up, 0 downAug 4, 2022$331.39M
    Mar 31, 2022$0.83$0.68$0.66 - $0.72+22.06%Beat0.0%60 up, 0 downApr 28, 2022$318.83M
    Dec 31, 2021$0.92$0.92$0.87 - $0.950.00%In line+1.1%70 up, 0 downFeb 14, 2022$311.03M
    Sep 30, 2021$1.08$0.91$0.88 - $0.94+18.68%Beat+80.0%8N/ANov 2, 2021$296.40M
    Jun 30, 2021$0.97$0.83$0.77 - $0.87+16.87%Beat+162.2%9N/AJul 29, 2021$272.74M
    Mar 31, 2021$0.83$0.66$0.64 - $0.67+25.76%Beat+25.8%5N/AApr 29, 2021$251.84M
    Dec 31, 2020$0.91$0.82$0.72 - $0.87+10.98%Beat+18.2%6N/AFeb 1, 2021$249.20M
    Sep 30, 2020$0.60$0.49$0.44 - $0.50+22.45%Beat-21.1%7N/AOct 27, 2020$213.70M
    Jun 30, 2020$0.37$0.23$0.01 - $0.46+60.87%Beat-44.8%8N/AJul 28, 2020$199.62M
    Mar 31, 2020$0.66$0.51$0.36 - $0.63+29.41%Beat+8.2%6N/AMay 7, 2020$229.69M
    Dec 31, 2019$0.77$0.78$0.77 - $0.79-1.28%Miss+10.0%7N/AFeb 6, 2020$248.29M
    Sep 30, 2019$0.76$0.71$0.70 - $0.72+7.04%Beat+20.6%7N/AOct 24, 2019$228.81M
    Jun 30, 2019$0.67$0.63$0.62 - $0.64+6.35%Beat+45.7%7N/AJul 25, 2019$217.41M
    Mar 31, 2019$0.61$0.41$0.39 - $0.41+48.78%Beat+110.3%7N/AApr 25, 2019$202.52M
    Dec 31, 2018$0.70$0.67$0.65 - $0.68+4.48%Beat+29.6%7N/AFeb 7, 2019$211.75M
    Sep 30, 2018$0.63$0.56$0.54 - $0.57+12.50%Beat+50.0%7N/AOct 25, 2018$204.27M
    Jun 30, 2018$0.46$0.39$0.38 - $0.41+17.95%Beat+48.4%7N/AJul 26, 2018$188.67M
    Mar 31, 2018$0.29$0.25$0.24 - $0.27+16.00%Beat+383.3%7N/AApr 26, 2018$182.62M
    Dec 31, 2017$0.54$0.52$0.51 - $0.53+3.85%Beat+45.9%7N/AFeb 1, 2018$196.37M
    Sep 30, 2017$0.42$0.42N/A0.00%In line+5.0%N/AN/AOct 26, 2017$186.75M
    Jun 30, 2017$0.31$0.23N/A+34.78%Beat-18.4%N/AN/AJul 27, 2017$181.04M
    Mar 31, 2017$0.06$0.02N/A+200.00%Beat-82.9%N/AN/AMay 4, 2017$148.55M
    Dec 31, 2016$0.37$0.41N/A-9.76%Miss-7.5%N/AN/AFeb 15, 2017$175.26M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.62, down 4.7% from the year before. It was $1.50 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.62-4.7%
    Dec 31, 2024$1.70-11.0%
    Dec 31, 2023$1.91-36.3%
    Dec 31, 2022$3.00-21.1%
    Dec 31, 2021$3.80+49.6%
    Dec 31, 2020$2.54-9.6%
    Dec 31, 2019$2.81+35.1%
    Dec 31, 2018$2.08+56.4%
    Dec 31, 2017$1.33-11.3%
    Dec 31, 2016$1.50N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,900 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,86313
    2026Q2Jun 30, 20267,16112
    2026Q1Mar 31, 20265,32112
    2025Q4Dec 31, 20258,27114
    2025Q3Sep 30, 20255,81312
    2025Q2Jun 30, 20255,83112
    2025Q1Mar 31, 20256,18112
    2024Q4Dec 31, 20245,97411

    2026Q3 Earnings Call

    Opening remarks

    David Unger VP of Investor Relations Good morning, and welcome to the Omnicell Third Quarter 2026 financial results conference call. My name is David Unger, Vice President of Investor Relations. On the call with me today are Randall Lipps, Chairman, Chief Executive Officer, and Founder; Nnamdi Njoku, President and Chief Operating Officer; and Baird Radford, Executive Vice President and Chief Financial Officer. Before we begin, I would like to remind you that today's call will include forward-looking statements within the meaning of federal securities laws, including statements regarding our financial outlook, business expectations, and strategic priorities. These forward-looking statements are based on current expectations and assumptions as of today and are subject to risks and uncertainties that could cause actual results to differ materially. For additional information concerning these risks and uncertainties, please refer to our earnings press release issued this morning, our annual report on Form 10-K filed with the SEC on February 26, 2026, and our subsequent SEC filings. We disclaim any obligation to update any forward-looking statements except as required by law. During this call, we will also discuss certain non-GAAP financial measures. Reconciliations of these measures to the most directly comparable GAAP measures are included in our third quarter 2026 earnings press release, available on the investor relations section of our website at ir.omnicell.com. Turning to today's agenda. Randall will begin with an overview of our third quarter performance and strategic priorities. Nnamdi will then provide an update on our operational execution and key initiatives, followed by Baird, who will review our financial results and updated outlook. We will then open the call for questions. With that, I will turn the call over to Randall. Randall?

    Randall Lipps Chairman, CEO, and Founder Good morning, everyone, and thank you for joining us. In the third quarter 2026, we delivered another quarter of strong execution. Total revenue was $308 million, and non-GAAP EBITDA was $45 million, both above the high end of our previously shared guidance. These results reflect the execution-oriented approach we've taken throughout the year and reinforce our confidence in the strategy we're pursuing in autonomous medication management. Medication management remains foundational to how health systems operate. We have seen that it is difficult for a hospital to achieve its clinical and operational objectives without getting medication management right, and that reality continues to underpin the long-term demand we see. Before sharing additional perspectives on our business, I want to touch on our sixth annual Illuminate event, held on September 29, where we brought customers and prospects together to discuss our strategy for medication management.

    Frequently Asked Questions About OMCL

    When is Omnicell's next earnings date?

    Omnicell's next earnings report is expected for Feb 3, 2027.

    Did OMCL beat earnings estimates last quarter?

    Yes. Omnicell reported EPS of $0.36 for the quarter ended Sep 30, 2026, above the $0.24 estimate, a 50.00% surprise.

    What EPS do analysts expect from OMCL next quarter?

    The consensus EPS estimate for Omnicell for the quarter ending Dec 31, 2026 is $0.39 from 10 analysts, with estimates from $0.14 to $0.45.

    How often does OMCL beat earnings estimates?

    Omnicell beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +45.53%.